Shattuck Labs, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $STTK in the last 30 days.
See all $STTK insider activity →Wedbush kept its Outperform rating on Shattuck Labs with a $14 price target, suggesting 104.7% upside from the Oct 1 close of $6.84. The target is based on a sum-of-parts valuation for SL-325. The firm also cited the appointment of Shoba Ravichandran as SVP of Clinical Development as a positive.
Analysts updated price targets for several companies. Argus raised Accenture's target to $260, Susquehanna cut CSX's to $55, and Rothschild upgraded Abbott Labs to Buy with a $127 target. Other notable changes include Synaptics, Nike, AtriCure, McCormick, Foghorn, Marathon, and Shattuck Labs.
Needham raised its price target for Shattuck Labs (STTK) to $19 from $17, citing plans for a Phase 2 trial of SL-325 in hidradenitis suppurativa. The stock has surged 87% year-to-date, with analysts maintaining a strong buy consensus. The company expects trial data in 2028, and the hidradenitis suppurativa market is projected to reach $5 billion by 2030. Multiple analysts have recently evaluated STTK, with varying price targets and ratings.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning STTK (Shattuck Labs, Inc.). Coverage has skewed bullish: 3 bullish, 1 neutral, and 0 bearish.
Recent STTK coverage spans financial news, market movers and earnings.
Wedbush kept its Outperform rating on Shattuck Labs with a $14 price target, suggesting 104.7% upside from the Oct 1 close of $6.84. The target is based on a sum-of-parts valuation for SL-325. The firm also cited the appointment of Shoba Ravichandran as SVP of Clinical Development as a positive.
Shattuck Labs may see modest upside.
Analyst upgrade signals potential upside as the trial could expand the drug's market opportunity.
The trial launch adds a new indication pipeline and may boost investor interest, but short‑term price impact is limited until data emerge.
Analyst initiation and strong buy rating likely support short-term upside.
AlphAI scores every news story that mentions STTK with an AI model for sentiment and relevance, and aggregates insider trades from Shattuck Labs, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Wedbush kept its Outperform rating on Shattuck Labs with a $14 price target, suggesting 104.7% upside from the Oct 1 close of $6.84. The target is based on a sum-of-parts valuation for SL-325. The firm also cited the appointment of Shoba Ravichandran as SVP of Clinical Development as a positive.
1 min readAnalysts updated price targets for several companies. Argus raised Accenture's target to $260, Susquehanna cut CSX's to $55, and Rothschild upgraded Abbott Labs to Buy with a $127 target. Other notable changes include Synaptics, Nike, AtriCure, McCormick, Foghorn, Marathon, and Shattuck Labs.
2 min readNeedham raised its price target for Shattuck Labs (STTK) to $19 from $17, citing plans for a Phase 2 trial of SL-325 in hidradenitis suppurativa. The stock has surged 87% year-to-date, with analysts maintaining a strong buy consensus. The company expects trial data in 2028, and the hidradenitis suppurativa market is projected to reach $5 billion by 2030. Multiple analysts have recently evaluated STTK, with varying price targets and ratings.
2 min readShattuck Labs (STTK) plans to start a Phase 2 trial in 2026 for SL-325 in hidradenitis suppurativa, with data expected in 2028. The company also appointed Shoba Ravichandran as Senior Vice President, Clinical Development. Cash runway is expected to last until 2029.
2 min readShattuck Labs (STTK) rose 4.91% after two analysts initiated coverage with positive ratings. TD Cowen rated it buy, while Raymond James gave a strong buy and $18 price target. Both highlighted SL-325, a drug candidate for inflammatory bowel disease, citing its novel mechanism. The company reported $208.3M in cash and expects funding into 2029. Phase 2b trial for SL-325 is set to start in Q3.
2 min readShattuck Labs (STTK) stock rose 4.91% on Monday after two analysts issued positive ratings. TD Cowen initiated coverage with a buy rating, while Raymond James gave a strong buy rating and $18 price target, more than double its recent close of $7.90. The optimism is driven by the company's SL-325 drug, which targets inflammatory bowel disease and has a potential $20 billion market, according to Raymond James.
2 min readAnalysts made several ratings changes: UBS upgraded Celestica to Buy with a $430 target, citing AI-driven demand. Citi initiated Reformation as Buy with a $20 target. Morgan Stanley initiated Jersey Mike's and ArcelorMittal as Overweight. Baird upgraded Darden to Outperform and downgraded Chipotle to Neutral. Other notable moves include upgrades for Suzano, Ionic Digital, and Fortune Brands, while Canada Goose was downgraded.
2 min readH.C. Wainwright cut its price target for Shattuck Labs (NASDAQ:STTK) to $14 from $18 while keeping a Buy rating, after Shattuck reported Q2 2026 results on Aug. 11. Shattuck expanded its RECEPTIVE-CD1 Phase 2b trial to three doses and ~232 patients. The SL-325 Crohn’s trial remains on track for a Q3 2026 start. The article also notes a $75M public offering and warrant exercises.
4 min readShattuck Labs, Inc. (STTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights – Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A bi
6 min readShattuck Labs (STTK) shares fell 1.8% pre-open after its Q2 2026 earnings. The company reported a net loss of $15.2 million versus $12.5 million a year earlier, and R&D rose 34% to $11.7 million. It cited favorable Phase 1 safety for SL-325 and said Phase 2b in Crohn’s is on track. Cash and investments were about $208.3 million.
5 min read
